Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era? - Wikidata - awgldk - TriplyDB

Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?

Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?

http://www.wikidata.org/entity/Q37577874

about

Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?

http://www.wikidata.org/entity/Q37577874

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Is There a Role for Minimal Re ...... n the Chemo-Immunotherapy Era?

@en

Is There a Role for Minimal Re ...... n the Chemo-Immunotherapy Era?

@nl

type

label

Is There a Role for Minimal Re ...... n the Chemo-Immunotherapy Era?

@en

Is There a Role for Minimal Re ...... n the Chemo-Immunotherapy Era?

@nl

prefLabel

Is There a Role for Minimal Re ...... n the Chemo-Immunotherapy Era?

@en

Is There a Role for Minimal Re ...... n the Chemo-Immunotherapy Era?

@nl

P1433

Q37577874-FAD35B5C-BD8B-4ADD-9117-89312A7AE596

P1476

Q37577874-9EB54AE9-9CEB-4EFE-82EA-A157B09527DF

P2093

Q37577874-683E421D-83A7-4049-8171-C18B8F909C81

Q37577874-CBBC68B6-C475-4037-8D57-AE9488CA2BD2

P2860

Q37577874-03E0D81A-0381-4AC5-AB5A-B6C3ED6FAD36

Q37577874-0BBB42AD-1469-4261-BA3B-0AE77E27BD15

Q37577874-0E66D2F8-1DF1-46B0-AADF-BEF84A0E2CDE

Q37577874-0F12D4EF-7750-4AD9-9979-780BFF7E316F

Q37577874-153A54BA-9870-4A92-B797-CF5B29ECF14D

Q37577874-184A932A-AB5A-429E-8B84-DF139678FFC2

Q37577874-1D7B97C0-D4A6-47DE-A211-3F18A911853D

Q37577874-27478613-4AED-49D4-B5A5-529D5857269E

Q37577874-2B6D79A0-6B51-408D-8A43-FE571D3C4323

Q37577874-2E9D7CCE-C4AC-4815-83DB-048F80A4AE8A

P304

Q37577874-7B093C99-FB2A-4209-B617-78C97867A637

P31

Q37577874-B430C9EC-395B-4EEF-80ED-0852F554D6FC

P356

Q37577874-A02C41F2-E19E-44B1-A6B8-5849BD05484E

P433

Q37577874-B36F113E-4D4F-41B0-B4CA-D7FA750C35DD

P478

Q37577874-CE749B10-7B31-4124-956D-B8176BB1A7AB

P50

Q37577874-76A45422-9141-40D4-B653-029C39C90097

P577

Q37577874-9D16F2DC-8397-4A7C-A3B2-77E695F5C052

P698

Q37577874-596F5968-8765-429E-99D7-8ADAB802640D

P921

Q37577874-FB32D55C-E366-43DC-ADFA-B1D48AB4087E

P932

Q37577874-11FC5C72-A731-4B9E-82D0-8506B80400FC

P356

P1433

Mediterranean journal of hematology and infectious diseases

P1476

Is There a Role for Minimal Re ...... n the Chemo-Immunotherapy Era?

@en

P2093

Alessandro Rambaldi

http://www.w3.org/2001/XMLSchema#string

Chiara Pavoni

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.

Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes.

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

P304

e2017010

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4084/MJHID.2017.010

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Gritti

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28101314

http://www.w3.org/2001/XMLSchema#string

P921

P932

5224815

http://www.w3.org/2001/XMLSchema#string